Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Intas launches biosimilar version of Rituximab
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Genzyme provides update on U.S. LEMTRADA™ filing
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
IFN-β inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis.
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Architecture of human mTOR complex 1.
Immune competence after alemtuzumab treatment of multiple sclerosis.
Mitoxantrone-related acute leukemia in MS: An open or closed book?
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Effect of IFN β-1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Refining diagnosis of multiple sclerosis with revised MRI criteria.
A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA).
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.
Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.
Santhera's Phase III program with Catena®/Raxone® in Duchenne muscular dystrophy on track to deliver pivotal data early in 2Q 2014
Breastfeeding and multiple sclerosis.
Adaptive myelination from fish to man.
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment

Pages